ProShares Ultra Nasdaq Biotechnology BIB
114.82 USD -10.57 (-8.43%)
Nov 5, 2026, 1:08 PM EST
115.00 Day range 124.12
67.50 52-week range 126.40
- YTD
- +43.92%
- 1 year
- +63.58%
- Market cap
- 107.60M
- EPS (ttm)
- 3.53
- P/E ratio
- 32.77
- YTD return
- +43.92%
- 1-year return
- +63.58%
- Volume
- 30.97K
- Avg volume
- 9.93K
- Open
- 124.12
- Previous close
- 125.39
- Day's range
- 115.00 – 124.12
- 52-week range
- 67.50 – 126.40
1M +8.83 (+8.26%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 59.52
- 200-day average
- 59.79
About ProShares Ultra Nasdaq Biotechnology
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
News
ProShares Announces ETF Share Splits 
Capital Investment Advisors LLC Acquires New Holdings in ProShares Ultra Nasdaq Biotechnology $BIB 
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Cross Below 50 Day Moving Average – What’s Next? 
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average – Here’s Why 
BIB: A Tactical 2 X Leveraged Biotech ETF 
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich 
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 
Equity CEFs/ETFs: Top Picks For 2024 - Part II 
Man in Germany Cured of HIV After Undergoing Stem Cell Transplant, According to Report in Nature Medicine 
The 7 Best ETFs to Buy to Cover 2023's Biggest Investing Opportunities
Your note
Sign in to keep a note on BIB — it syncs with the Stock Master app.